TITLE

Seaside Raises $30M Series B for Autism Work

PUB. DATE
September 2009
SOURCE
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the 30 million dollars Series B raised by Seaside Therapeutics LLC for the funding of its activities on autism in Cambridge, Massachusetts. It states that Seaside has raised the money from a private family investment firm to fund its work on autism. It adds that neuroscience professor Mark Bear is the one studying the role of mGluR5 in Fragile X syndrome.
ACCESSION #
44369835

 

Related Articles

  • Decoding Autism. LANGRETH, ROBERT // Forbes Asia;Dec2010, Vol. 6 Issue 14, p114 

    The article offers information on the research work of neuroscientist Mark Bear regarding the treatment of some forms of autism and mental retardation with the drugs available in the medicine field. It mentions that an inherited disease called fragile X syndrome which causes autism can be...

  • Autism drug hope. Coghlan, Andy // New Scientist;5/11/2013, Vol. 218 Issue 2916, p7 

    The article reports on the results of a 2013 clinical trial of the autism drug arbaclofen (STX209) by the pharmaceutical company Seaside Therapeutics, finding that the reduction of brain activity by the drug improved appropriate social responses but not social withdrawal symptoms.

  • Seaside Therapeutics Blazes a Trail in Fragile X. Shaffer, Catherine // BioWorld Today;6/3/2011, Vol. 22 Issue 107, p1 

    The article reports on the Phase III trial of Seaside Therapeutics Inc. of a possible drug to treat core symptoms of Fragile X syndrome. It discusses the function of the drug compound STX209 in moderating the gamma-amino butyric acid type B (GABA-B) receptor in autism and disorders of brain...

  • Seaside Therapeutics raises $30 million in financing.  // PharmaWatch: CNS;Nov2009, Vol. 8 Issue 11, p13 

    The article reports on the 30 million dollars raised by Seaside Therapeutics, a private investment firm institutionalized in the research of autism and fragile x syndrome. The fund will be spent to improve therapeutic nominees suffering from such condition. According to the president and chief...

  • Seaside Therapeutics Seeks Regulatory Path in Fragile X. Morrison, Trista // BioWorld Insight;8/2/2010, Vol. 18 Issue 31, p2 

    The article reports the endpoints on a pivotal program for STX209 in fragile X syndrome, a genetic mental disorder commonly known cause of autism and designed by Seaside Therapeutics Inc., in order to gain an approval from the Food and Drug Administration (FDA). It is noted that STX209 didn't...

  • Fragile X and Tuberous Sclerosis 'Mirror Images.'. Breindl, Anette // BioWorld Today;11/30/2011, Vol. 22 Issue 231, p1 

    The article reports on the conclusion reached by scientists from Massachusetts Institute of Technology after comparing the brains of mice with disorders on the autism spectrum. Their experiments showed that genetic alterations that have opposing effects on neural activity can lead to disorders...

  • Clinic Roundup.  // BioWorld Today;9/10/2010, Vol. 21 Issue 175, p4 

    This section offers news briefs related to biotechnology. An international Phase II study of FBS0701, an iron chelator, was initiated by FerroKin BioSciences Inc. Seaside Therapeutics Inc. has revealed data from a Phase II trial of its drug for autism spectrum disorders. A Phase I trial of TG02,...

  • Seaside Shores up Funding with $30M Series B for Autism Work. Boggs, Jennifer // BioWorld Today;9/18/2009, Vol. 20 Issue 180, p1 

    The article reports on the 30 million U.S. dollars in Series B financing raised by Seaside Therapeutics LLC. The financing was obtained from a private family investment firm which has pledged to fund its development activities via commercialization. The company has already garnered some 66...

  • Seaside Therapeutics Wants Robust Effects On Fragile X. Breindl, Anette // BioWorld Today;12/26/2007, Vol. 18 Issue 248, p1 

    The article reports on the lead program of Seaside Therapeutics that focuses on the treatment of Fragile X syndrome. According to company Chief Executive Officer (CEO) Randy Carpenter, their aim is to come up with treatments for autism spectrum disorders. Under the program, the company will make...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics